Genfit plans US listing as NASH drugmakers race to the finish line
As the race to develop NASH treatments heats up, French drug developer Genfit (Euronext: $GNFT) is planning to list itself in the United States as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
